Literature DB >> 28503557

Epidemiology and risk factors: intrahepatic cholangiocarcinoma.

Amar Gupta1, Elijah Dixon1.   

Abstract

Intrahepatic cholangiocarcinoma (ICC) is a rare entity with a distinct clinical course and epidemiology from hilar and extrahepatic cholangiocarcinoma. ICC makes up 8-10% of cholangiocarcinomas and 10-20% of all primary liver tumors. There remains a considerable amount of geographic variation in the incidence of ICC worldwide; however, the overall incidence of this malignancy appears to be rising. Several risk factors have been identified, such as infectious causes (liver flukes, viral hepatitis), biliary tract disease [primary sclerosing cholangitis (PSC), hepaticolithiasis, biliary cystic diseases], metabolic syndrome, lifestyle choices (alcohol abuse, tobacco use), and cirrhosis. Despite this, a substantial number of ICC patients do not have any identifiable risk factors, underlining the need for further work into the pathogenesis of this malignancy.

Entities:  

Keywords:  Intrahepatic cholangiocarcinoma (ICC); epidemiology; risk factors

Year:  2017        PMID: 28503557      PMCID: PMC5411279          DOI: 10.21037/hbsn.2017.01.02

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN: 2304-3881            Impact factor:   7.293


  27 in total

Review 1.  Intrahepatic cholangiocarcinoma: management options and emerging therapies.

Authors:  Rebecca M Dodson; Matthew J Weiss; David Cosgrove; Joseph M Herman; Ihab Kamel; Robert Anders; Jean-Francois H Geschwind; Timothy M Pawlik
Journal:  J Am Coll Surg       Date:  2013-07-24       Impact factor: 6.113

Review 2.  Multidisciplinary approaches to intrahepatic cholangiocarcinoma.

Authors:  Shishir K Maithel; T Clark Gamblin; Ihab Kamel; Celia Pamela Corona-Villalobos; Melanie Thomas; Timothy M Pawlik
Journal:  Cancer       Date:  2013-08-20       Impact factor: 6.860

3.  Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin.

Authors:  Mina Komuta; Bart Spee; Sara Vander Borght; Rita De Vos; Chris Verslype; Raymond Aerts; Hirohisa Yano; Tetsuya Suzuki; Masanori Matsuda; Hideki Fujii; Valeer J Desmet; Masamichi Kojiro; Tania Roskams
Journal:  Hepatology       Date:  2008-05       Impact factor: 17.425

4.  Carcinogenicity of perfluorooctanoic acid, tetrafluoroethylene, dichloromethane, 1,2-dichloropropane, and 1,3-propane sultone.

Authors:  Lamia Benbrahim-Tallaa; Béatrice Lauby-Secretan; Dana Loomis; Kathryn Z Guyton; Yann Grosse; Fatiha El Ghissassi; Véronique Bouvard; Neela Guha; Heidi Mattock; Kurt Straif
Journal:  Lancet Oncol       Date:  2014-08       Impact factor: 41.316

5.  Hepatitis B and C virus, Clonorchis sinensis for the risk of liver cancer: a case-control study in Pusan, Korea.

Authors:  H R Shin; C U Lee; H J Park; S Y Seol; J M Chung; H C Choi; Y O Ahn; T Shigemastu
Journal:  Int J Epidemiol       Date:  1996-10       Impact factor: 7.196

6.  Hepatitis C and hepatitis B nucleic acids are present in intrahepatic cholangiocarcinomas from the United States.

Authors:  Vivekanandan Perumal; Jianzhou Wang; Paul Thuluvath; Michael Choti; Michael Torbenson
Journal:  Hum Pathol       Date:  2006-07-18       Impact factor: 3.466

7.  Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States.

Authors:  Luciana McLean; Tushar Patel
Journal:  Liver Int       Date:  2006-11       Impact factor: 5.828

8.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

9.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

10.  Case series of 17 patients with cholangiocarcinoma among young adult workers of a printing company in Japan.

Authors:  Shoji Kubo; Yasuni Nakanuma; Shigekazu Takemura; Chikaharu Sakata; Yorihisa Urata; Akinori Nozawa; Takayoshi Nishioka; Masahiko Kinoshita; Genya Hamano; Hiroaki Terajima; Gorou Tachiyama; Yuji Matsumura; Terumasa Yamada; Hiromu Tanaka; Shoji Nakamori; Akira Arimoto; Norifumi Kawada; Masahiro Fujikawa; Hiromitsu Fujishima; Yasuhiko Sugawara; Shogo Tanaka; Hideyoshi Toyokawa; Yuko Kuwae; Masahiko Ohsawa; Shinichiro Uehara; Kyoko Kogawa Sato; Tomoshige Hayashi; Ginji Endo
Journal:  J Hepatobiliary Pancreat Sci       Date:  2014-01-13       Impact factor: 7.027

View more
  42 in total

1.  Prognostic value of multiple epithelial mesenchymal transition-associated proteins in intrahepatic cholangiocarcinoma.

Authors:  Xiangguo Tian; Zhixin Cao; Qian Ding; Zhen Li; Chunqing Zhang
Journal:  Oncol Lett       Date:  2019-06-24       Impact factor: 2.967

2.  Ablative therapies for intrahepatic cholangiocarcinoma.

Authors:  Antonio Giorgio; Pietro Gatti; Paolo Matteucci; Valentina Giorgio
Journal:  Hepatobiliary Surg Nutr       Date:  2018-06       Impact factor: 7.293

3.  Role of Lymph Node Dissection in Small (≤ 3 cm) Intrahepatic Cholangiocarcinoma.

Authors:  Andrea Ruzzenente; Simone Conci; Luca Viganò; Giorgio Ercolani; Serena Manfreda; Fabio Bagante; Andrea Ciangherotti; Corrado Pedrazzani; Antonio D Pinna; Calogero Iacono; Guido Torzilli; Alfredo Guglielmi
Journal:  J Gastrointest Surg       Date:  2019-02-28       Impact factor: 3.452

4.  Correlation of LARP1 and E-cadherin expression with prognosis of intrahepatic cholangiocarcinoma.

Authors:  Fei Jiang; De-Bao Fang; Jie Lin; Qiang Chen; Li-Xin Zhu; Hong-Zhu Yu
Journal:  Int J Clin Exp Pathol       Date:  2018-07-01

5.  A model for predicting post-liver transplantation recurrence in intrahepatic cholangiocarcinoma recipients.

Authors:  Ao Ren; Zhongqiu Li; Xuzhi Zhang; Ronghai Deng; Yi Ma
Journal:  J Gastrointest Oncol       Date:  2020-12

Review 6.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

7.  Inhibition of TLR7 and TLR9 Reduces Human Cholangiocarcinoma Cell Proliferation and Tumor Development.

Authors:  Fatma El Zahraa Mohamed; Rajiv Jalan; Shane Minogue; Fausto Andreola; Abeba Habtesion; Andrew Hall; Alison Winstanley; Steven Olde Damink; Massimo Malagó; Nathan Davies; Tu Vinh Luong; Amar Dhillon; Rajeshwar Mookerjee; Dipok Dhar; Rajai Munir Al-Jehani
Journal:  Dig Dis Sci       Date:  2021-05-03       Impact factor: 3.199

Review 8.  Virus-Driven Carcinogenesis.

Authors:  Yuichiro Hatano; Takayasu Ideta; Akihiro Hirata; Kayoko Hatano; Hiroyuki Tomita; Hideshi Okada; Masahito Shimizu; Takuji Tanaka; Akira Hara
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 9.  The Role of Surgical Resection and Liver Transplantation for the Treatment of Intrahepatic Cholangiocarcinoma.

Authors:  Guergana Panayotova; Jarot Guerra; James V Guarrera; Keri E Lunsford
Journal:  J Clin Med       Date:  2021-05-30       Impact factor: 4.241

10.  Comparison of liver biopsies before and after direct-acting antiviral therapy for hepatitis C and correlation with clinical outcome.

Authors:  Omar A Saldarriaga; Bradley Dye; Judy Pham; Timothy G Wanninger; Daniel Millian; Michael Kueht; Benjamin Freiberg; Netanya Utay; Heather L Stevenson
Journal:  Sci Rep       Date:  2021-07-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.